Combined Pharmacotherapy for Cannabis Dependency (D-LUCS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01020019
Recruitment Status :
First Posted : November 25, 2009
Results First Posted : May 11, 2016
Last Update Posted : April 24, 2019
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Frances R Levin, National Institute on Drug Abuse (NIDA)
Participants were treated at the Substance Treatment and Research Service (STARS) of Columbia University/ New York State Psychiatric Institute (NYSPI). Study enrollment occurred from January 2010 through May 2014 with study completion in September 2014.
The study included a one-week placebo lead-in phase. Participants were randomized at the end of the placebo lead-in phase and those who reported marijuana use less than once a week during the lead-in phase were considered placebo responders and were not randomized. A total of 34 participants discontinued prior to randomization for various reasons.
Lofexidine and Dronabinol
Lofex. matched placebo Dronabinol p...
Maintained at 1.8mg/day Lofex. and ...
Lofex. matched placebo Dronabinol placebo
Placebo: Placebo control
Maintained at 1.8mg/day Lofex. and 60 mg/day of Dronabinol
Lofexidine and Dronabinol: Lofex: .6 mg/ TID Dronabinol: 20 mg/TID